Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

facturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to fund operations through the primary endpoint analysis of its Phase 3 clinical registration trial progress and timing of clinical trials for Specifid, including difficulties or delays in development, testing, manufacturing and marketing Specifid or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for Specifid or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of Specifid and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of Specifid for use in clinical trials and, if Specifid receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using Specifid; potential delays in patient enrollme
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Strategic marketing and branding agency, Red House Group, ... The agency was founded in 2008 by Jenny Taylor ... to expand its business each year. “We have evolved ... focus on branding and marketing strategy. As we look ... identity to reflect who we have become while also ...
(Date:3/6/2015)... YORK , March 6, 2015  Attorney ... claims on behalf of purchasers of the securities ... (NasdaqGS: OREX -News).  Such investors ... or his investor relations coordinator Eitan Kimelman ... The investigation concerns whether Orexigen and certain ...
(Date:3/6/2015)... Transparency Market Research has published a new report titled ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”. ... at US$ 116.3 Mn in 2013 and is anticipated to ... of 5.1% from 2014 to 2020. In terms of volume, ... in 2013. , Isoxaflutole is widely used in the growth ...
(Date:3/5/2015)... YORK , March 5, 2015  DuPont (NYSE: ... Morgan Aviation, Transportation and Industrials Conference held today in ... President Matthew L. Trerotola discussed strategy, progress ... Materials segments for DuPont.  Strengthening and growing the company,s ... the three areas of strategic priority for DuPont. ...
Breaking Biology Technology:Red House Group Reveals New Identity as Able&Co. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc. 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4
... launch of a new series of web-based training programs for professionals ... courses are one hour in duration and designed specifically for the ... ... Salt Lake City, Utah (PRWEB) December 11, 2008 -- ...
... Schering-Plough Corporation (NYSE: SGP ) today declared a quarterly ... made on Feb. 27, 2009, to shareholders of record at the ... 30, 2008, there were 1,626,234,628 common shares outstanding. , ... declared a quarterly dividend of $3.75 per share on the 2007 ...
... of Hematology Annual Meeting , , ... ACEL ) today announced that American Society of Hematology ... Abstract 4205 & 2008 112: Abstract 4010) report that ONCONASE ... leukemia (CLL) and acute myeloblastic leukemia (AML) cells alone as ...
Cached Biology Technology:McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 2McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... discovery of a much sought after crack in the armor ... of the world,s population, causing stomach ulcers and other diseases. ... chemical pathway that the bacteria need for survival. Their study, ... these hard-to-treat microbes, is scheduled for the October 16 issue ...
... Exposure to radon gas in homes is the second leading ... carried out by researchers from the University of Cantabria and ... on exposure to this element in a uranium mining area ... Madrid. Numerous studies worldwide have shown that radon, a ...
... researchers at the University of California, Berkeley, has identified ... muscle. By manipulating these pathways, the researchers were able ... restoring its ability to repair and rebuild itself. ... issue of the journal EMBO Molecular Medicine , ...
Cached Biology News:Study in Spain and Romania confirms radon as second leading cause of lung cancer 2Study in Spain and Romania confirms radon as second leading cause of lung cancer 3Scientists discover clues to what makes human muscle age 2Scientists discover clues to what makes human muscle age 3Scientists discover clues to what makes human muscle age 4
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: